6-K - Scinai Immunotherapeutics Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Scinai Immunotherapeutics Ltd. announced the completion of its acquisition of 100% of the shares of Recipharm Israel Ltd., which operates a cGMP manufacturing site in Yavne, Israel, and entered into a long-term strategic commercial collaboration with Recipharm. The transactions expand Scinai’s CDMO manufacturing footprint and capabilities, enabling end-to-end development and manufacturing services.

Key Takeaways

1Scinai acquired 100% of Recipharm Israel Ltd. shares via Share Purchase Agreement.

2Recipharm Israel Ltd. operates cGMP site in Yavne, Israel, for early chemistry development and small-scale API manufacturing.

3Acquisition structured as share purchase to preserve operational continuity, including employees, quality systems, and customer contracts.

4Entered Commercial Collaboration Agreement with Recipharm for mutual preferred partner status across development lifecycle.

5Collaboration includes Master Quality Agreement and Tech Transfer Framework Agreement.

6Expanded capabilities cover recombinant proteins, small molecules, peptides, antibodies, and oligonucleotides.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Transaction Details

Acquisition / Disposition

Target: Recipharm Israel Ltd. (100% shares, operates Yavne site)
Consideration: Financial terms confidential
Structure: Share Purchase Agreement

•Completed on 2026-02-17
•Transferred with appropriate working capital for operational continuity

Material Agreement

Agreement: Commercial Collaboration Agreement
Parties: Scinai Immunotherapeutics Ltd., Recipharm

•Scinai as preferred partner for early-stage development in Recipharm ecosystem
•Recipharm as preferred partner for Scinai’s late-stage clinical and commercial manufacturing
•Access to Recipharm’s global manufacturing network under predefined terms
•Mutual client project referrals and shared economics
•Master Quality Agreement and Tech Transfer Framework Agreement to be established

Exhibits (2)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

PRESS RELEASE DATED FEBRUARY 17, 2026